SNX16

Across TCGA pan-cancer cohorts, SNX16 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SNX16 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SNX16 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SNX16 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

HNSC, PDAC, and LSCC are the cancer types where SNX16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	All	1.000	0.185	.010	36	view →
PDAC	OS	Median	All	0.980	0.710	.006	18	view →
LSCC	OS	Median	II,III,IV	0.851	0.597	.022	11	view →
UCEC	OS	Tertile	III,IV	0.306	0.807	.022	8	view →
CCRCC	OS	Median	II,III,IV	0.650	0.846	.035	3	view →
LUAD	DFS	Quartile	III,IV	0.261	0.671	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SNX16–HNSC (OS)

Open the HNSC breakdown →